Adam Adler, Ph.D.
Chief Scientific Officer
Dr. Adler has more than fifteen years of research and laboratory management experience, including deep expertise in antibody sequencing. At GigaGen, he leads laboratory research operations and is responsible for the development of GigaGen’s product pipeline in oncology and immune deficiency. He has used his expertise in cutting-edge technologies including microfluidics, protein engineering and genomics to create GigaGen’s immune analysis and drug discovery technologies that have enabled rapid pipeline development. Prior to GigaGen, Dr. Adler held research management roles at LakePharma, where he was responsible for all internal and external projects including developing new antibody sequence analysis tools, and at Genentech where he worked to identify novel oncogenes and validate cancer drug targets. Dr. Adler has authored over 25 research publications in leading journals and holds a B.A. in Biological Sciences from Northwestern University and a Ph.D. in Cancer Biology from Stanford University School of Medicine.